Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Bryce C Simes, Gordon G MacGregor Alabama College of Osteopathic Medicine, Dothan, AL, USACorrespondence: Bryce C SimesAlabama College of Osteopathic Medicine, 445 Health Sciences Blvd., Dothan, AL 36303, USATel +1 205 904-504-8897Fax +1 205 334-699-2268Email simesbc@acom.eduAbstract: This comprehen...

Full description

Bibliographic Details
Main Authors:	Simes BC, MacGregor GG
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-10-01
Series:	Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:	SGLT2 inhibitors type 2 diabetes Canagliflozin Empagliflozin Dapagliflozin Ertugliflozin
Online Access:	https://www.dovepress.com/sodium-glucose-cotransporter-2-sglt2-inhibitors-a-clinicians-guide-peer-reviewed-article-DMSO

Similar Items

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014-10-01)

High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes
by: Ajay Aggarwal, et al.
Published: (2019-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
by: Anastasios Tentolouris, et al.
Published: (2019-08-01)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
by: Reed JW
Published: (2016-10-01)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
by: Sanjay Kalra, et al.
Published: (2015-01-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014-12-01)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
by: Matthew Griffin, et al.
Published: (2020-08-01)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019-04-01)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes
by: Juan José Rodríguez, et al.
Published: (2018-01-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement
by: Sanjay Kalra, et al.
Published: (2017-01-01)

SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01)

Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
by: Salem A. Beshyah
Published: (2016-06-01)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
by: Beatriz Fernandez-Fernandez, et al.
Published: (2020-06-01)

Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy
by: Devon J. Pace, et al.
Published: (2018-11-01)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01)

Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
by: T. S. Panevin, et al.
Published: (2020-06-01)

New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
by: V. V. Salukho, et al.
Published: (2020-05-01)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
by: Milton Packer
Published: (2019-10-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction
by: Ahmed S. Ahmed, et al.
Published: (2021-07-01)

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
by: Sin-Hee Park, et al.
Published: (2021-03-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
by: Francesca Iannantuoni, et al.
Published: (2019-11-01)

Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2
by: Mohamed A. Morsy, et al.
Published: (2021-09-01)

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
by: Masa-Ki Inoue, et al.
Published: (2019-07-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)